Homocysteine as a potential biomarker in bipolar disorders: A critical review and suggestions for improved studies

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 7, 2015, Pages 927-939

  Ghanizadeh, Ahmad ^a,b   Singh, Ajeet B ^c   Berk, Michael ^c,d   Torabi Nami, Mohammad ^b,e  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c DEAKIN UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biomarker; Bipolar disorder; Folic acid; Homocysteine; One carbon; Oxidative stress

Indexed keywords

C REACTIVE PROTEIN; HOMOCYSTEINE; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

AMINO ACID BLOOD LEVEL; BIPOLAR DISORDER; DEPRESSION; DISEASE COURSE; GENETIC POLYMORPHISM; HUMAN; MOOD DISORDER; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; METABOLISM; METHODOLOGY; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BIOMARKERS; BIPOLAR DISORDER; HOMOCYSTEINE; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; RESEARCH DESIGN;

EID: 84931037929     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1019866     Document Type: Review

References (93)

1. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64(5):543-52
2. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011;68(3):241-51
3. Dilsaver SC. An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord 2011;129(1-3):79-83
4. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEPBD). Am J Psychiatry 2006;163(2):217-24
5. Ghanizadeh A, Akhondzadeh S, Hormozi M, et al. Glutathione-related factors and oxidative stress in autism, a review. Curr Med Chem 2012;19(23):4000-5
6. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992;55(1):131-8
7. Hu CY, Qian ZZ, Gong FF, et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphism susceptibility to schizophrenia and bipolar disorder: an updated meta-analysis. J Neural Transm 2015;122(2):307-20
8. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10(1):111-13
9. Peerbooms OL, van Os J, Drukker M, et al. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? Brain Behav Immun 2011;25(8):1530-43
10. Boldyrev AA. Molecular mechanisms of homocysteine toxicity. Biochemistry (Mosc) 2009;74(6):589-98
11. Nabi H, Bochud M, Glaus J, et al. Association of serum homocysteine with major depressive disorder: results from a large population-based study. Psychoneuroendocrinology 2013;38(10):2309-18
12. Folstein M, Liu T, Peter I, et al. The homocysteine hypothesis of depression. Am J Psychiatry 2007;164(6):861-7
13. Dietrich-Muszalska A, Malinowska J, Olas B, et al. The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem Res 2012;37(5):1057-62
14. Ghanizadeh A. Increased glutamate and homocysteine and decreased glutamine levels in autism: A review and strategies for future studies of amino acids in autism. Dis Markers 2013;35(5):281-6
15. Gabryelewicz T, Styczynska M, Luczywek E, et al. The rate of conversion of mild cognitive impairment to dementia: predictive role of depression. Int J Geriatr Psychiatry 2007;22(6):563-7
16. Permoda-Osip A, Dorszewska J, Bartkowska-Sniatkowska A, et al. Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression. Pharmacopsychiatry 2013;46(6):227-8
17. Almeida OP, Flicker L, Yeap BB, et al. Aspirin decreases the risk of depression in older men with high plasma homocysteine. Transl Psychiatry 2012;2:e151
18. Ozbek Z, Kucukali CI, Ozkok E, et al. Effect of the methylenetetrahydrofolate reductase gene polymorphisms on homocysteine, folate and vitamin B12 in patients with bipolar disorder and relatives. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(5):1331-7
19. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000;61(Suppl 6):4-6
20. Stahl SM. Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. CNS Spectr 2007;12(10):739-44
21. Abdolmaleky HM, Smith CL, Faraone SV, et al. Methylomics in psychiatry: Modulation of geneenvironment interactions may be through DNA methylation. Am J Med Genet B Neuropsychiatr Genet 2004;127B(1):51-9
22. Gortz P, Hoinkes A, Fleischer W, et al. Implications for hyperhomocysteinemia: not homocysteine but its oxidized forms strongly inhibit neuronal network activity. J Neurol Sci 2004;218(1-2):109-14
23. Kruman II, Culmsee C, Chan SL, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20(18):6920-6
24. de Sousa RT, Machado-Vieira R, Zarate CA Jr, Manji HK. Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder. Expert Opin Ther Targets 2014;18(10):1131-47
25. Ghanizadeh A, Berk M. Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia. Med Gas Res 2013;3(1):11
26. Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013;11:200
27. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013;18(5):595-606
28. de Sousa RT, Zarate CA Jr, Zanetti MV, et al. Oxidative stress in early stage Bipolar Disorder and the association with response to lithium. J Psychiatr Res 2014;50:36-41
29. Berk M, Berk L, Dodd S, et al. Stage managing bipolar disorder. Bipolar Disord 2014;16(5):471-7
30. Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis 2011;34(1):3-15
31. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1994;91(14):6369-73
32. Carpenter LL, Gawuga CE, Tyrka AR, et al. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology 2010;35(13):2617-23
33. Aschbacher K, O'Donovan A, Wolkowitz OM, et al. Good stress, bad stress and oxidative stress: insights from anticipatory cortisol reactivity. Psychoneuroendocrinology 2013;38(9):1698-708
34. Smolin LA, Benevenga NJ, Berlow S. The use of betaine for the treatment of homocystinuria. J Pediatr 1981;99(3):467-72
35. Fries GR, Pfaffenseller B, Stertz L, et al. Staging and neuroprogression in bipolar disorder. Curr Psychiatry Rep 2012;14(6):667-75
36. Susser E, Brown AS, Klonowski E, et al. Schizophrenia and impaired homocysteine metabolism: A possible association. Biol Psychiatry 1998;44(2):141-3
37. Williams LJ, Bjerkeset O, Langhammer A, et al. The association between depressive and anxiety symptoms and bone mineral density in the general population: The HUNT Study. J Affect Disord 2011;131(1-3):164-71
38. Wang Y, Liu X, Zhang D, et al. The effects of apoptosis vulnerability markers on the myocardium in depression after myocardial infarction. BMC Med 2013;11:32
39. O'Neil A, Williams ED, Stevenson CE, et al. Co-morbid cardiovascular disease and depression: sequence of disease onset is linked to mental but not physical selfrated health. Results from a crosssectional, population-based study. Soc Psychiatry Psychiatr Epidemiol 2012;47(7):1145-51
40. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 2011;25(2):181-213
41. Slopen N, Kubzansky LD, McLaughlin KA, Koenen KC. Childhood adversity and inflammatory processes in youth: A prospective study. Psychoneuroendocrinology 2013;38(2):188-200
42. Gabbay V, Klein RG, Alonso CM, et al. Immune system dysregulation in adolescent major depressive disorder. J Affect Disord 2009;115(1-2):177-82
43. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early-vs. latestage bipolar disorder. Int J Neuropsychopharmacol 2009;12(4):447-58
44. Maes M, Berk M, Goehler L, et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 2012;10:66
45. Steiner J, Walter M, Gos T, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 2011;8:94
46. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012;338(6103):68-72
47. Anda RF, Butchart A, Felitti VJ, Brown DW. Building a framework for global surveillance of the public health implications of adverse childhood experiences. Am J Prev Med 2010;39(1):93-8
48. Padmos RC, Van Baal GC, Vonk R, et al. Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: A twin study. Arch Gen Psychiatry 2009;66(9):957-65
49. Delport D, Schoeman R, van der Merwe N, et al. Significance of dietary folate intake, homocysteine levels and MTHFR 677 C>T genotyping in South African patients diagnosed with depression: test development for clinical application. Metab Brain Dis 2014;29(2):377-84
50. Forti P, Rietti E, Pisacane N, et al. Blood homocysteine and risk of depression in the elderly. Arch Gerontol Geriatr 2010;51(1):21-5
51. Almeida OP, McCaul K, Hankey GJ, et al. Homocysteine and depression in later life. Arch Gen Psychiatry 2008;65(11):1286-94
52. Ford AH, Flicker L, Singh U, et al. Homocysteine, depression and cognitive function in older adults. J Affect Disord 2013;151(2):646-51
53. Ebesunun MO, Eruvulobi HU, Olagunju T, Owoeye OA. Elevated plasma homocysteine in association with decreased vitamin B(12), folate, serotonin, lipids and lipoproteins in depressed patients. Afr J Psychiatry (Johannesbg) 2012;15(1):25-9
54. Osher Y, Bersudsky Y, Silver H, et al. Neuropsychological correlates of homocysteine levels in euthymic bipolar patients. J Affect Disord 2008;105(1-3):229-33
55. Osher Y, Sela BA, Levine J, Belmaker RH. Elevated homocysteine levels in euthymic bipolar disorder patients showing functional deterioration. Bipolar Disord 2004;6(1):82-6
56. Levine J, Sela BA, Osher Y, Belmaker RH. High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(7):1181-91
57. Ezzaher A, Mouhamed DH, Mechri A, et al. Hyperhomocysteinemia in Tunisian bipolar I patients. Psychiatry Clin Neurosci 2011;65(7):664-71
58. Bromberg A, Bersudsky Y, Levine J, Agam G. Global leukocyte DNA methylation is not altered in euthymic bipolar patients. J Affect Disord 2009;118(1-3):234-9
59. Chiarani F, Tramontina JF, Cereser KM, et al. Homocysteine and other markers of cardiovascular risk during a manic episode in patients with bipolar disorder. Rev Bras Psiquiatr 2013;35(2):157-60
60. Dias VV, Brissos S, Cardoso C, et al. Serum homocysteine levels and cognitive functioning in euthymic bipolar patients. J Affect Disord 2009;113(3):285-90
61. Doganavsargil Baysal GO, Gokmen Z, Akbaş H, et al. [Association of serum homocysteine and methionine levels with cognition and functioning in bipolar disorder]. Turk Psikiyatri Derg 2013;24(1):7-16
62. Davis J, Maes M, Andreazza A, et al. Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. Mol Psychiatry 2014. [Epub ahead of print]
63. Dittmann S, Seemüller F, Schwarz MJ, et al. Association of cognitive deficits with elevated homocysteine levels in euthymic bipolar patients and its impact on psychosocial functioning: preliminary results. Bipolar Disord 2007;9(1-2):63-70
64. Taylor MJ, Carney SM, Goodwin GM, Geddes JR. Folate for depressive disorders: systematic review and metaanalysis of randomized controlled trials. J Psychopharmacol 2004;18(2):251-6
65. Bedson E, Bell D, Carr D, et al. Folate augmentation of treatment-evaluation for depression (FolATED): randomised trial and economic evaluation. Health Technol Assess 2014;18(48):vii-viii; 1-159
66. Behzadi AH, Omrani Z, Chalian M, et al. Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: A double-blind randomized controlled trial. Acta Psychiatr Scand 2009;120(6):441-5
67. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry 2013;70(1):31-41
68. Goyette P, Sumner JS, Milos R, et al. Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. Nat Genet 1994;7(4):551
69. Karagiannis TC, Maulik N. Factors influencing epigenetic mechanisms and related diseases. Antioxid Redox Signal 2012;17(2):192-4
70. Kinoshita M, Numata S, Tajima A, et al. DNA methylation signatures of peripheral leukocytes in schizophrenia. Neuromolecular Med 2013;15(1):95-101
71. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE review. Am J Epidemiol 2007;165(1):1-13
72. Cohen-Woods S, Craig I, Gaysina D, et al. The bipolar association case-control study (BACCS) and meta-analysis: no association with the 5,10-Methylenetetrahydrofolate reductase gene and bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2010;153B(7):1298-304
73. Zintzaras E, Ziogas DC, Kitsios GD, et al. MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: A meta-analysis. Pharmacogenomics 2009;10(8):1285-94
74. Permoda-Osip A, Dmitrzak-Weglarz M, Hauser J, Rybakowski JK. Are genes connected with homocysteine metabolism associated with bipolar disorder? Neuropsychobiology 2014;69(2):107-11
75. Sibani S, Christensen B, O'Ferrall E, et al. Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria. Hum Mutat 2000;15(3):280-7
76. Kempisty B, Bober A, Luczak M, et al. Distribution of 1298A>C polymorphism of methylenetetrahydrofolate reductase gene in patients with bipolar disorder and schizophrenia. Eur Psychiatry 2007;22(1):39-43
77. Singh AB, Bousman CA, Ng C, Berk M. Antidepressant pharmacogenetics. Curr Opin Psychiatry 2014;27(1):43-51
78. Dong E, Chen Y, Gavin DP, et al. Valproate induces DNA demethylation in nuclear extracts from adult mouse brain. Epigenetics 2010;5(8):730-5
79. Gorjipour F, Asadi Y, K Osguei N, et al. Serum level of homocysteine, folate and vitamin-B12 in epileptic patients under carbamazepine and sodium valproate treatment: A systematic review and meta-analysis. Iran Red Crescent Med J 2013;15(3):249-53
80. Iglesias-Gutierrez E, Egan B, Díaz-Martínez A E, et al. Transient increase in homocysteine but not hyperhomocysteinemia during acute exercise at different intensities in sedentary individuals. PLoS One 2012;7(12):e51185
81. Hayashino Y, Jackson J, Hirata T, et al. Effects of exercise on C-reactive protein, inflammatory cytokine and adipokine in patients with type 2 diabetes: A metaanalysis of randomized controlled trials. Metabolism 2014;63(3):431-40
82. Stahl Z, Belmaker RH, Friger M, Levine J. Nutritional and life style determinants of plasma homocysteine in schizophrenia patients. Eur Neuropsychopharmacol 2005;15(3):291-5
83. Esfahani A, Wong JM, Truan J, et al. Health effects of mixed fruit and vegetable concentrates: A systematic review of the clinical interventions. J Am Coll Nutr 2011;30(5):285-94
84. Xiao Y, Zhang Y, Wang M, et al. Dietary protein and plasma total homocysteine, cysteine concentrations in coronary angiographic subjects. Nutr J 2013;12(1):144
85. Cao L, Lou X, Zou Z, et al. Folic acid attenuates hyperhomocysteinemiainduced glomerular damage in rats. Microvasc Res 2013;89:146-52
86. Jacka FN, Maes M, Pasco JA, et al. Nutrient intakes and the common mental disorders in women. J Affect Disord 2012;141(1):79-85
87. Bamashmoos SA, Al-Nuzaily MA, Al-Meeri AM, Ali FH. Relationship between total homocysteine, total cholesterol and creatinine levels in overt hypothyroid patients. Springerplus 2013;2:423
88. Campesi I, Carru C, Zinellu A, et al. Regular cigarette smoking influences the transsulfuration pathway, endothelial function, and inflammation biomarkers in a sex-gender specific manner in healthy young humans. Am J Transl Res 2013;5(5):497-509
89. Park SB, Georgiades A. Changes in body composition predict homocysteine changes and hyperhomocysteinemia in Korea. J Korean Med Sci 2013;28(7):1015-20
90. Dittmann S, Seemüller F, Grunze HC, et al. The impact of homocysteine levels on cognition in euthymic bipolar patients: A cross-sectional study. J Clin Psychiatry 2008;69(6):899-906
91. Permoda-Osip A, Dorszewska J, Skibinska M, et al. Hyperhomocysteinemia in bipolar depression: clinical and biochemical correlates. Neuropsychobiology 2013;68(4):193-6
92. Vuksan-Cusa B, Sagud M, Jakovljevic M, et al. Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia. Nord J Psychiatry 2012;67(5):320-5
93. Vuksan-Cusa B, Jakovljević M, Sagud M, et al. Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics. Psychiatry Res 2011;189(1):21-5